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ABSTRACT 
 
Rationale: Experimental studies have shown a potential blood pressure (BP) lowering effect of 
red wine polyphenols, while the effects of ethanol and polyphenols on BP in humans are not yet 
clear.    
 
Objective: The aim of the present work was to evaluate the effects of red wine fractions 
(alcoholic and non-alcoholic) on BP and plasma nitric oxide (NO) in subjects at high 
cardiovascular risk. 
 
Methods and Results: Sixty-seven men at high cardiovascular risk were studied. After a 2-week 
run-in period, subjects were randomized into three treatment periods in a cross-over clinical trial, 
with a common background diet plus red wine (30g alcohol/d), the equivalent amount of 
dealcoholized red wine, or gin (30g alcohol/d), lasting 4 weeks each intervention. At baseline 
and after each intervention, anthropometrical parameters, BP and plasma NO were measured.  
Systolic and diastolic BP decreased significantly after the dealcoholized red wine intervention 
and these changes correlated with increases in plasma NO. 
 
Conclusions: Dealcoholized red wine decreases systolic and diastolic BP. Our results point out 
through a NO-mediated mechanism. The daily consumption of dealcoholized red wine could be 
useful for the prevention of low to moderate hypertension. Trial registered at controlled-
trials.com: ISRCTN88720134. 
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Non-standard Abbreviations:  
 
ANCOVA analysis of covariance 
ANOVA analysis of variance 
BP  blood pressure 
CHD  coronary heart disease 
DBP  diastolic blood pressure 
DRW  dealcoholized red wine 
G  gin 
HDL  high density cholesterol 
LDL  low density cholesterol 
NO  nitric oxide 
RW  red wine 
SBP  systolic blood pressure  
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Introduction 
 
Epidemiological evidence has associated moderate alcohol consumption with decreased 
cardiovascular risk1. However, red wine (RW) seems to confer greater protective effects 
because of its high polyphenolic content. In vitro and experimental studies have shown a 
potential blood pressure (BP)-lowering effect and/or enhancement of endothelial nitric oxide 
(NO) production by RW2. It is unclear whether these effects can be extrapolated to humans, 
since the amount of RW polyphenols used in these studies is usually higher than that achieved 
through moderate RW consumption. Recently, small amounts of RW, but not other alcoholic 
beverages, were shown to increase plasma NO concentrations3. While the negative effects of 
heavy or binge alcohol drinking on BP are well known, the effects of moderate alcohol 
consumption are controversial, since some studies have observed a linear trend and others a 
non-linear or J-shaped association, independently of the beverage consumed4-6. Therefore, the 
aim of the present study was to evaluate the effects of RW fractions (alcoholic and non-
alcoholic) on BP and plasma NO concentration in high cardiovascular risk subjects. 
 
 
Methods 
 
The study was an open, randomized, cross-over, controlled clinical trial comprising 
three 4-week periods. Detailed Methods have been published7 and are provided in the Online 
Supplement. 
 
Seventy-three men at high cardiovascular risk, aged between 55 and 75 years were 
included in the study. All subjects had diabetes mellitus or >3 cardiovascular disease risk 
factors7. After a 2-week run-in period wherein subjects were asked not to consume any 
alcoholic beverage, they were randomized using a computer-generated table into three 
treatments in a cross-over design, with a common background diet plus gin (100mL – 30g 
ethanol/day), RW (272mL – 30g ethanol/day; total polyphenols: 798 Eq Gallic Acid/day -
EGA/day-), and the same amount of polyphenols as RW in the form of dealcoholized red wine 
(DRW) (272mL - total phenols: 733 EGA/day), resulting in six possible beverage sequences 
lasting 4 weeks each intervention. No washout periods were included between the interventions. 
 
After the run-in period (baseline) and the day after each intervention period (RW, DRW 
and gin), BP and heart rate were measured 3 times at 5-min intervals on the nondominant arm 
with an oscillometer (Omron 705 CP; Omron Matsusaka Co Ltd, Matsusaka City, Japan) after 
15 minutes resting in a seated position. The mean of the second and the third measures was 
considered for statistical analysis. 
 
Fasting blood samples for the NO analyses were collected at baseline and after each 
intervention, and stored at –80°C until assayed. For measurement of NO, the release of NO2- 
and NO3-, the stable breakdown products of NO in plasma, were determined by a 
chemiluminescence detector in a NO analyzer (Sievers Instruments, Inc., Boulder, CO). 
 
Statistical analyses were performed using the Statistical Analysis Systems (version 9.2, 
SAS Institute Inc, Cary, NC). To analyze the changes within each treatment a Student’s t test for 
paired samples was performed between the data obtained before and after each intervention. 
One-factor analysis of variance (ANOVA) for repeated measures and the Bonferroni post-hoc 
test were used to compare the differences of the changes in outcome variables between the 
interventions. See Online Supplement for further details of statistical analyses. 
 
RESULTS 
 
The baseline characteristics of the 67 subjects who completed the study are detailed in 
Table 1. Reasons for exclusion of 6 participants are described in the Online Supplement. No 
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significant differences in body mass index, waist-to-hip ratio and heart rate were observed 
(Table 2). Systolic BP (SBP) and diastolic BP (DBP) decreased significantly after the DRW 
intervention (P=0.0001 and 0.017, respectively) (Figure 1). These changes were significantly 
different from those observed after the gin intervention (P=0.026 and 0.045 for SBP and DPB, 
respectively) (Table 2).  Plasma NO concentration increased after the DRW intervention 
(P=0.041) and the change was also significantly different from that observed after the gin 
intervention (P=0.026). The changes in BP and NO after the DRW period were correlated 
(r=0.598; P<0.001 and r=0.362; P=0.002 for SBP and DBP, respectively; On-line Supplemental 
Figure I). The intervention with RW did not differ from the DRW and gin interventions, 
although SBP and DBP tended to decrease and NO tended to increase after the RW intervention 
compared to the gin period (P=0.069, 0.075 and 0.079 for SBP, DBP and NO, respectively). In 
addition, changes in SBP correlated with changes in NO after the RW intervention (r=0.251, 
P=0.035). Exclusion of participants with hypertension or antihypertensive treatment did not 
materially change the results (Online Supplemental Table I). Intervention compliance and 
dietary data during the three interventions are also shown in the Online Supplement. No 
carryover effect was observed for any outcome. 
 
 
Discussion 
 
After the 4-week interventions with RW, DRW and gin in a crossover study in high 
cardiovascular risk subjects, we observed that DRW decreased SBP and DBP while increasing 
plasma NO concentration. RW tended to have similar effects to those of DRW but BP changes 
were non-significant and gin had no effect. Therefore, the BP-lowering and NO-raising effects 
should be attributed to the RW polyphenols and not to alcohol, which seems to counteract the 
effects of the non-alcoholic fraction of RW.  
 
Botden et al. observed that RW polyphenol consumption for 4 weeks did not affect the 
BP in subjects with high-normal BP or grade 1 hypertension8 or in healthy young women9 and 
postulated that RW polyphenols could only favorably affect BP in subjects with endothelial 
dysfunction8. Our study included subjects with high-normal BP or grade 1 hypertension, but we 
did not measure endothelial function. However, considering the load of cardiovascular risk 
factors of the study subjects, their probability of having endothelial dysfunction was very high. 
On the other hand, Huang et al.3 reported increased plasma NO in healthy volunteers consuming 
100mL/day of RW during 3 weeks, but not when they consumed equivalent amounts of alcohol 
as beer or vodka, although no BP changes were reported after any intervention. 
 
The results of our study point out that moderate alcohol consumption does not affect BP. 
Okubo et al.6 observed a J-shaped association between alcohol consumption and BP changes in 
a normotensive population, with a threshold effect at 18mL of daily ethanol consumption. 
Besides, the meta-analysis of Xin et al.10 described a dose-response relationship between the 
reduction of alcohol consumption in heavy alcohol drinkers (≥3 drinks/d) and the reduction of 
BP. We studied moderate alcohol consumers who followed a run-in period with abstention from 
alcohol, and 4 weeks of moderate consumption of RW or gin had little effect on BP, suggesting 
that moderate alcohol consumption does not affect BP, at least in high cardiovascular risk 
subjects. These results concur with those of Frisoli et al.4 and Stranges et al.11, who observed no 
consistent association of beer, wine or liquor consumption with the risk of hypertension. 
Stranges et al.11 also observed that drinking outside meals increased the risk of hypertension 
independently of the amount of alcohol consumed. Our study subjects were advised to consume 
the beverages during meals and this may explain, in part, why moderate alcohol consumption 
did not affect BP.  
 
Finally, although the BP reduction after DRW consumption was modest (5.8 and 2.3 
mmHg of SBP and DBP, respectively), decreases of 4 or 2 mm Hg in SBP or DBP respectively, 
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have been associated with a 14% and 20% reduction in CHD and stroke risk, respectively12, 
conferring clinical significance to our results, especially in the case of DRW.  
 
Our study has limitations. A 4-week intervention may not represent the potential effects 
of long-term consumption. In addition, the specific substances responsible for the observed 
effects could not be identified and endothelial function was not measured. In conclusion, DRW 
decreases SBP and DBP, possibly through a NO-mediated mechanism. Therefore, the daily 
consumption of DRW may be useful for the prevention of low to moderate hypertension.  
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FIGURE LEGEND 
 
Figure 1. Blood pressure and plasma nitric oxide in the 67 subjects studied.   *Comparisons 
between before and after the interventions (Student’s t test for paired samples). Before each 
intervention is the value of the previous intervention or the baseline in the first intervention. 
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TABLES 
 
Table 1. Baseline characteristics of the study subjects. 
 
 Mean ± SD*
Age (years) 60 ± 8 
Current smokers [n (%)] 16 (23.9) 
Sedentarism [n (%)] 40 (59.7) 
Family history of premature CHD [n (%)] 52 (77.6) 
Type-2 diabetes [n (%)] 15 (22.4) 
Hypertension [n (%)] 38 (56.7) 
Dyslipemia [n (%)] 16 (23.9) 
Medications [n (%)]  
     ACE Inhibitors 28 (41.8) 
     Diuretics 5 (7.5) 
     Statins 22 (32.8) 
     Oral hypoglycemic drugs 14 (20.9) 
     Aspirin or antiplatelet drugs 15 (22.4) 
Triglycerides (mg/dL) 128 ± 60 
Total cholesterol (mg/dL) 204 ± 33 
LDL-cholesterol (mg/dL) 133 ± 32 
HDL-cholesterol (mg/dL) 43 ± 7 
LDL/HDL ratio 3.08 ± 0.10 
 
*Mean ± SD or n (%), when indicated (n=67). CHD, coronary heart disease; ACE, angiotensin-
converting enzyme. 
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Table 2. Changes in anthropometric parameters, blood pressure and plasma concentrations of nitric 
oxide in the 67 subjects studied after the 3 interventions. 
 
 
Results expressed as mean differences (95% CI) between after and before each intervention. Before 
each intervention is the value of the previous intervention or the baseline (run-in period) in the first 
intervention. *P value of the repeated-measures ANOVA from the differences between interventions. 
Values in a row with different superscript letters are significantly different (P<0.05, Bonferroni post-
hoc test). 
 Red wine intervention Dealcoholized red wine intervention Gin intervention P
* 
Body mass index 
(kg/m2) 0.6 (-0.7, 0.2) -0.1 (-0.4, 0.1) -0.1 (-0.3, 0.1) 0.200 
Waist-to-hip ratio -0.006 (-0.013, 0.001) -0.001 (-0.006, 0.005) 0.007 (-0.002, 0.015) 0.118 
Systolic blood 
pressure (mm Hg) -2.3 (-5.1, 0.5)
a,b -5.8 (-8.9, -2.7)a, -0.8 (-4.1, 2.5)b 0.028 
Diastolic blood 
pressure (mm Hg) -1.0 (-2.5, 0.5)
a,b -2.3 (-4.1, -0.4)a, 0.1 (-1.8, 1.9)b 0.027 
Heart rate 
(beats/min) -0.2 (-1.9, 1.5) -1.7 (-3.4, 0.1) 1.1 (-0.8, 3.0) 0.187 
Nitric oxide 
(µmol/L) 0.6 (-3.3, 4.3)
a,b 4.1 (0.5, 7.6)a, -1.4 (-4.1, 1.3)b 0.022 
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Novelty and Significance 
 
What Is Known? 
 
 Hypertension is a major cardiovascular risk factor, and is associated with decreased life 
expectancy. 
 
 Endothelial secretion of nitric oxide (NO), a potent vasodilator, contributes to lower 
blood pressure. 
 
 In experimental studies, dietary compounds such as polyphenols (contained in fruits, 
vegetables and fermented alcoholic beverages such as red wine) have been shown to 
stimulate the secretion of endothelial NO, potentially decreasing blood pressure. 
 
 The relationship between moderate alcohol consumption and blood pressure has not 
been clearly established. 
 
 
What New Information Does This Article Contribute? 
 
 Moderate red wine consumption (alcohol plus polyphenols) does not significantly affect 
blood pressure or NO production. 
 
 Moderate gin consumption (alcohol without polyphenols) does not significantly affect 
blood pressure or NO production. 
 
 Dealcoholized red wine consumption (red wine polyphenols without alcohol) 
significantly decreases systolic and diastolic blood pressure and increases plasma NO 
concentration. 
 
 
Although an inverse relationship between moderate alcohol consumption and the incidence of 
hypertension has been described, the effects of the different alcoholic beverage fractions 
(alcoholic and non-alcoholic) on blood pressure are unclear. We observed that moderate alcohol 
consumption, independently of beverage type (red wine or gin) did not significantly affect blood 
pressure, but dealcoholized red wine, decreased blood pressure and these changes were 
correlated with plasma NO increases. The findings provide new insights into the role of t dietary 
components such as red wine polyphenols in cardiovascular health, particularly in blood 
pressure regulation. Consumption of dealcoholized red wine might be useful in preventing low 
to moderate-degree hypertension. 
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 17 
Subjects 18 
A total of 73 high-risk subjects aged between 55 and 75 years were recruited for the 19 
study in the outpatient clinic of the Internal Medicine Department at our Institution. The 20 
subjects included in the trial were moderate alcohol consumers (1-3 drinks/day) and 21 
had diabetes mellitus or ≥3 of the following cardiovascular disease risk factors: active 22 
smoking, hypertension, plasma LDL cholesterol >160 mg/dL, plasma HDL cholesterol 23 
<35 mg/dL, overweight or obesity (body mass index ≥25 kg/m2), and/or family history of 24 
premature coronary heart disease (CHD). Exclusion criteria included documented 25 
CHD, stroke or peripheral vascular disease, human immunodeficiency virus infection, 26 
alcoholic liver disease, malnutrition and neoplastic or acute infectious diseases. None 27 
of the study subjects were consumers of multivitamin or vitamin E supplements or anti-28 
inflammatory drugs (steroids, non-steroidal anti-inflammatory agents or aspirin at doses 29 
>100 mg/day). 30 
After a 2-week run-in period wherein subjects were asked not to consume any 31 
alcoholic beverage, they were randomized using a computer-generated table into three 32 
treatments in a cross-over design, with a common background diet plus gin (100mL – 33 
30g ethanol/day), RW (272mL – 30g ethanol/day; total polyphenols: 798 Eq Gallic 34 
Acid/day -EGA/day-), and the same amount of polyphenols as RW in the form of 35 
dealcoholized red wine (DRW) (272mL - total phenols: 733 EGA/day), resulting in six 36 
possible beverage sequences lasting 4 weeks each intervention. No washout periods 37 
were included between the interventions. 38 
The Institutional Review Board of the hospital approved the study protocol, and 39 
all participants gave written consent before participation in the study. This trial was 40 
registered at controlled-trials.com as ISRCTN88720134. 41 
 42 
Diet and exercise monitoring 43 
Subjects were asked to exclude alcoholic beverages 2 weeks before the first 44 
intervention (run-in period) and throughout the study. They were also asked not to 45 
change their dietary habits or level of physical activity during the study. Natural foods 46 
rich in antioxidants, especially fruit and vegetables, were especially monitored so that 47 
individual diets had similar antioxidant content throughout the study. Given the 48 
characteristics of the tested beverages, participants were not blinded to the type of 49 
drink they ingested. At the beginning of the study and after each intervention period, a 50 
medical record and Minnesota Leisure Time Physical Activity Questionnaire validated 51 
in Spain4 were administered, and a 7-d food record questionnaire (5 weekdays and 2 52 
weekend days), also validated in our population5 was used to assess nutrient intake 53 
and to monitor adherence to the study protocol. The dietary information was converted 54 
into nutrient data using the Food Processor Nutrition and Fitness Software (esha 55 
Research, Salem, OR). Subjects were asked to maintain their lifestyle habits and to 56 
report any illness or abnormality presented during the study period. At the end of each 57 
study sequence, a clinician assessed any adverse effects from the interventions by 58 
administering a checklist of symptoms, including bloating, fullness, or indigestion, 59 
altered bowel habit, dizziness and other symptoms possibly associated with 60 
consumption of the test beverages. 61 
 62 
Composition of wines 63 
The RW and DRW were from the Penedès appellation and elaborated with the Merlot 64 
grape variety. The total phenolic content of the three beverages was determined with 65 
the Folin-Ciocalteu method1, the phenolic profile of RW and DRW was determined by 66 
HPLC-DAD as described previously2 and resveratrol and piceid content was 67 
determined by HPLC-DAD as described by Romero-Perez et al3. There were no 68 
significant differences between the phenolic composition of RW and DRW (ref. 7 of the 69 
main manuscript). 70 
 71 
Laboratory Analyses 72 
After the run-in period (baseline) and the day after the end of each intervention period 73 
(RW, DRW and gin), BP and heart rate were measured 3 times at 5-min intervals on 74 
the nondominant arm with an oscillometer (Omron 705 CP; Omron Matsusaka Co Ltd, 75 
Matsusaka City, Japan) after 15 minutes resting in a seated position. The mean of the 76 
second and the third measures was considered for statistical analysis. 77 
 Fasting blood samples for the NO analyses and safety biochemistry 78 
determinations were collected at baseline and after each intervention, and stored at –79 
80°C until assayed. For measurement of NO, the rele ase of NO2- and NO3-, the stable 80 
breakdown products of NO in plasma, were determined by a chemiluminescence 81 
detector in a NO analyzer (Sievers Instruments, Inc., Boulder, CO). Plasma 82 
aminotransferases (ASAT and ALAT), gamma glutamyl transpeptidase (GGT) and 83 
albumin were measured by molecular absorption spectrometry and vitamin B12 and 84 
serum and intraerythrocytary folic acid concentrations by immunoanalyses. 85 
 86 
Compliance assessment 87 
Resveratrol conjugates derived from phase II metabolism were measured in 24-h urine 88 
samples from the last day of the run-in period and the last day of each intervention, 89 
using the validated methodology described by Urpi-Sarda et al.6 quantitatively adapted 90 
to the commercial and available standards. trans- and cis-Resveratrol-3-O-glucuronide 91 
(98% purity each), cis-resveratrol-4’-O-glucuronide (96% purity) and trans-resveratrol-92 
3-O-sulfate (98% purity) were purchased from Toronto Research Chemicals Inc. (North 93 
York, ON, Canada). trans- and cis-Resveratrol-4’-O-sulfate and cis-resveratrol-3-O-94 
sulfate were quantified using the trans-resveratrol-3-O-sulfate calibration curve. 95 
Ethylglucuronide was measured in 24-h urine samples as a biomarker of alcohol intake 96 
by liquid chromatography (LC) (Agilent series 1200) coupled with a hybrid quadrupole 97 
time-of-flight (TOF) QSTAR Elite (Applied Biosystems/MDS Sciex). 98 
 99 
Statistical analyses 100 
Statistical analyses were performed using the SAS Statistical Analysis Systems 101 
(version 9.2, SAS Institute Inc, Cary, NC). Descriptive statistics [mean ± standard 102 
deviation (SD)] were used to describe the baseline characteristics of the participants. 103 
To exclude the presence of a carryover effect for the three periods, the interaction 104 
between treatment (RW, DRW and gin) and period (1rst, 2nd and 3rd) was analyzed by 105 
the repeated measures Analysis of Covariance (ANCOVA) with the baseline values 106 
(the values of the previous intervention or the run-in period if the first intervention) as 107 
the covariates. To analyze the changes within each treatment a Student’s t test for 108 
paired samples was performed between the data obtained before and after each 109 
intervention. One-factor analysis of variance (ANOVA) for repeated measures and the 110 
Bonferroni post-hoc test were used to compare the differences of the changes in 111 
outcome variables between the interventions. Pearsons’ correlation analysis was used 112 
to quantify relationships between changes in blood pressure and nitric oxide plasma 113 
concentrations.  Within- and between-group differences are expressed as means and 114 
95% confidence intervals (CI). P was considered significant when <0.05. 115 
Supplemental Results 116 
Baseline characteristics, intervention compliance, diet, exercise monitoring, and 117 
side effects 118 
 119 
Of the 73 subjects included, six withdrew before completing the three phases of the 120 
study because of physical illness (n = 2), journeys (n = 2) or taste intolerance to DRW 121 
(n = 2). Therefore, 67 subjects completed the study. Most were overweight or obese 122 
(∼91%), more than half the population had hypertension (∼57%), more than three 123 
quarters had a family history of cardiovascular disease (∼78%), and more than one fifth 124 
had dyslipemia (∼24%), type-2 diabetes (∼22%) or were active smokers (∼24%). 125 
Biochemical safety analytes (serum and intraerythrocytary folic acid, vitamin B12, 126 
albumin, ASAT, ALAT and GGT) remained within the normal range throughout the 127 
study. None of the subjects reported adverse effects related to the interventions. 128 
Protocol adherence was optimum in all subjects, and complete agreement was 129 
observed between the participants' reports and the number of empty bottles returned. 130 
As a measure of intervention compliance, a sum of total resveratrol metabolites -a 131 
marker of RW and DRW consumption7- was determined in 24-h urine samples 132 
collected the last day of the run-in period and the last day of each intervention. After 133 
consumption of RW and DRW, 24-h urinary excretion of total resveratrol metabolites 134 
increased above baseline from 0.94 µmol (95% CI: 0.43, 1.46 µmol) to 6.04 µmol (95% 135 
CI: 4.76, 7.31 µmol) and 6.28 µmol (95% CI: 5.10, 7.46 µmol), respectively (P < 0.001, 136 
both). Resveratrol metabolites concentrations were not statistically different after DRW 137 
and RW interventions (P = 1.00) and were significantly higher after RW and DRW 138 
interventions compared to gin period [0.51 µmol (95% CI: 0.08, 0.94 µmol); P ≤ 0.001]. 139 
After the gin intervention, urinary resveratrol metabolites were similar to baseline 140 
values (P = 1.00). Urinary ethylglucuronide concentrations, a biomarker of alcohol 141 
consumption, increased significantly after the RW and gin periods compared to 142 
baseline values, with increases of 342% (95% CI: 245, 773%) and 256% (95% CI: 179, 143 
599%), respectively (P < 0.001, both). Moreover, concentrations after the RW and gin 144 
interventions were also higher than those obtained after DRW: 634% (95% CI: 468, 145 
1424%) and 491% (95% CI: 359, 1121), respectively (P < 0.001, both). No significant 146 
differences were observed between the DRW and baseline periods [66% (95% CI: 64, 147 
75%); P = 1.000] and between the RW and gin interventions [24% (95% CI: 24, 25%); 148 
P = 1.000]. According to these results, compliance with the three interventions was 149 
excellent.  150 
Exclusion of the participants with hypertension or under antihypertensive 151 
treatment did not materially change the results (Online Table I). Nevertheless, in the 152 
hypertensive subgroup, the diastolic blood pressure and the plasma nitric oxide 153 
concentrations remained practically unchanged during the study. Interestingly, we 154 
observed that baseline BMI and waist-to-hip ratios were significantly different between 155 
the hypertensive and the non-hypertensive subgroup (P=0.009 and 0.047, respectively, 156 
Student’s t test for independent samples), without changes throughout the study. 157 
Dietary intake data for the three intervention periods are shown in Online Table 158 
II. No significant changes from baseline in energy, nutrient, mineral, and antioxidant 159 
intake or in the daily average energy expended in physical activity were observed. 160 
Likewise, none of the study subjects reported changes in medication use throughout 161 
the study. No carryover effect was observed for any outcome, and the values before 162 
each intervention were not significantly different between them for any of the outcomes.  163 
Supplemental Data  
On-line Supplemental Figure I: Correlation between the changes in blood pressure and nitric oxide between before and after each 
intervention in the 67 subjects studied. 
 
 
Online Supplemental Table I: Comparison of anthropometric parameters, blood pressure and plasma concentrations of nitric oxide between 
38 hypertensive and 29 non-hypertensive subjects at baseline and after the 3 interventions (n=67). 
 
  Red wine intervention Dealcoholized red wine intervention Gin intervention  
  Mean±SD* Mean differences (95% CI)† Mean± SD
 
* 
Mean differences 
(95% CI)† Mean± SD
 
* 
Mean differences 
(95% CI)†  
  Before After Before After Before After P‡ 
Body mass index (kg/m2) Total 29.4 ± 3.8 29.5 ± 3.9 0.6 (-0.7, 0.2) 29.3 ± 3.9 29.4 ± 4.1 -0.1 (-0.4, 0.1) 29.4 ± 3.8 29.5 ± 4.0 -0.1 (-0.3, 0.1) 0.200 
 Hypertensive 30.9 ± 4.2 30.9 ± 4.3 0.2 (-0.1, 0.4) 30.9 ± 4.5 30.9 ± 4.3 -0.1 (-0.2, 0.2) 30.8 ± 4.4 30.9 ± 4.3 -0.2 (-0.5, 0.1) 0.084 
 
Non-
hypertensive 28.4 ± 3.1 28.3 ± 3.2 -0.1 (-0.2, 0.1) 28.4 ± 3.0 28.3 ± 3.2 0.1 (-0.3, 0.4) 28.4 ± 3.2 28.2 ± 4.0 -0.1 (-0.5, 0.2) 0.876 
Waist-to-hip ratio Total 0.97 ± 0.04 0.97 ± 0.05 -0.006 (-0.013, 0.001) 0.97 ± 0.04 0.97 ± 0.05 -0.001 (-0.006, 0.005) 0.98 ±0.05 0.98 ± 0.05 0.007 (-0.002, 0.015) 0.118 
 Hypertensive 0.99 ± 0.06 0.98 ± 0.05 -0.009 (-0.020, 0.003) 0.98 ± 0.05 0.98 ± 0.05 -0.001 (-0.010, 0.008) 0.98 ± 0.05 0.99 ±  0.06 0.003 (-0.010, 0.017) 0.400 
 
Non-
hypertensive 0.97 ± 0.04 0.96 ± 0.04 -0.003 (-0.012, 0.006) 0.96 ± 0.04 0.96 ±  0.04 -0.001 (-0.008, 0.006) 0.97 ± 0.04 0.97 ±  0.05 0.011 (-0.001, 0.022) 0.202 
Systolic blood pressure (mm Hg) Total 137 ± 16 135 ± 15 -2.3 (-5.1, 0.5)a,b 138 ± 18 132 ± 16 -5.8 (-8.9, -2.7)a,§ 138 ± 17 136 ± 19 -0.8 (-4.1, 2.5)b 0.028 
 Hypertensive 139 ± 19 138 ± 15 -2.4 (-6.2, 1.5)a,b 143 ± 20 136 ±18 -7.7 (-12.2, -3.0)a,§ 138 ± 19 139 ± 18 0.8 (-3.5, 5.1)b 0.024 
 
Non-
hypertensive 134 ± 13 131 ± 14a -2.1 (-6.5, 2.3)
a,b
 133 ± 16 129 ±15 -3.5 (-7.8, -0.8)a,§ 135 ± 15 134 ± 19 -1.0 (-8.0, 2.0)b 0.042 
Diastolic blood pressure (mm Hg) Total 80 ± 8 79 ± 9 -1.0 (-2.5, 0.5)a,b 79 ± 10 77 ± 8 -2.3 (-4.1, -0.4)a,§ 79 ± 8 79 ± 10 0.1 (-1.8, 1.9)b 0.027 
 Hypertensive 80 ± 10 78 ± 10 -2.1 (-4.6, 0.3) 80 ± 11 77 ± 9 -2.2 (-4.8, 0.5) 78 ± 10 78 ± 9 -0.4 (-2.4, 1.7) 0.401 
 
Non-
hypertensive 79 ± 7 79 ± 9 -0.8 (-4.2, 0.5)
a,b
 78 ± 9 77 ± 8 -2.7 (-5.6, -0.6)a,§ 79 ± 7 80 ± 11 2.3 (-0.1, 4.9)b 0.015 
Heart rate (beats/min) Total 68 ± 10 68 ± 10 -0.2 (-1.9, 1.5) 67 ± 9 68 ± 9 -1.7 (-3.4, 0.1) 68 ± 10 69 ± 11 1.1 (-0.8, 3.0) 0.187 
 Hypertensive 69 ± 12 68 ± 12 -1.2 (-3.7, 1.2) 67 ± 9 67 ± 10 -0.7 (-4.2, 1.0) 68 ± 11 69 ± 12 1.2 (-2.0, 4.4) 0.428 
 
Non-
hypertensive 68 ± 8 69 ± 9 0.3 (-2.0, 2.6) 68 ± 10 69 ± 8 -1.4 (-3.9, 1.1) 68 ± 8 69 ± 11 1.1 (-1.3, 3.6) 0.499 
Nitric oxide (µmol/L) Total 27.5 ± 15.8 27.8 ± 13.0 0.6 (-3.3, 4.3)a,b 26.1 ± 12.1 29.6 ± 17.8 4.1 (0.5, 7.6)a,§ 27.1 ± 11.4 25.8 ± 12.0 -1.4 (-4.1, 1.3)b 0.022 
 Hypertensive 28.1 ± 19.1 27.4 ± 13.7 -0.8 (-8.2, 6.5) 24.8 ± 9.7 27.1 ±14.1 2.2 (-2.6, 7.1) 27.1 ± 10.7 25.8 ± 11.2 -2.0 (-6.4, 2.3) 0.464 
 
Non-
hypertensive 26.8 ± 10.9 28.2 ± 12.5 2.1 (-0.5, 4.8)
a,b
 27.8 ± 14.1 32.0 ± 19.3 5.7 (0.2, 11.2)a,§ 27.0 ± 12.4 25.8 ± 12.8 -1.0 (-4.6, 2.5)b 0.015 
Results are expressed as *mean ± SD (n=38 and n=29 for the hypertensive and the non-hypertensive population) and †mean differences (95% 
CI) between after and before each intervention. Before each intervention is the value of the previous intervention or the baseline in the first 
intervention. ‡P value of the repeated-measures ANOVA from the differences between interventions. §Significant differences (P<0.05) between 
after and before the intervention, measured by a Student’s t test for paired samples. No significant differences were found between the values 
before each intervention for any of the outcomes (repeated-measures ANOVA).
Online Supplemental Table II: Daily energy and nutrient intakes in the 67 subjects studied at baseline and after the three interventions*. 
 
  
Red wine intervention Dealcoholized red wine intervention Gin intervention 
  
 Mean± SD † Mean differences Mean± SD † Mean differences Mean± SD † Mean differences  
  Before After (95% CI)‡ Before After (95% CI)‡ Before After (95% CI)‡ P§ 
Energy (kcal/d) 1863 ± 256 1782 ± 325  -85 (-238, 67) 1804 ± 396 1862 ± 320 90 (-63, 244) 1896 ± 403 1887 ± 336  -15 (-183, 153) 0.359 
Total protein (g/d) 92.63 ± 16.92 89.06 ± 18.35  -2.3 (-9.9, 9.5) 93.15 ± 15.78 94.29 ± 17.56 2.3 (-8.3, 8.8) 92.1 ± 2.0 95.04 ± 18.73 1.8 (-8.2, 11.8) 0.967 
Carbohydrates (g/d) 205 ± 37 201 ± 44  -6.3 (-32, 30) 184 ± 40 193 ± 38 14.4 (-12.3, 41.3) 194 ± 39 206 ± 40 13.2 (-7.8, 34.2) 0.763 
Dietary fiber (g/d) 22.31 ± 8.2 20.63 ± 8.08  -2.1 (-5.7, 1.5) 17.85 ± 5.14 19.88 ± 6.82 1.6 (-1.2, 4.4) 19.53 ± 9.04 22.05 ± 10.01 1.6 (-1.1, 4.4) 0.277 
Sugars (g/d) 71.77 ± 20.08 66.74 ± 25.59  -9.7 (-19.6, 0.2) 61.36 ± 23.34 67.33 ± 20.08 6.5 (-4.7, 17.8) 68.88 ± 23.84 70.11 ± 20.84 2.1 (-10.3, 14.4) 0.153 
Total lipids (g/d) 75.51 ± 13.99 72.72 ± 16.27  -5.7 (-13.9, 2.5) 73.48 ± 19.31 78.55 ± 20.41 9.1 (-1.3, 19.6) 73.70 ± 23.16 79.86 ± 21.89  -0.6 (-11.5, 10.3) 0.118 
SFA (g/d) 19.86 ± 4.93 18.40 ± 7.06  -0.7 (-3.4, 2.0) 17.36 ± 8.33 18.90 ± 6.15 3.9 (-0.3, 7.4) 19.20 ± 6.51 19.01 ± 5.48  -1.0 (-4.9, 2.8) 0.128 
MUFA (g/d) 36.99 ± 7.30 35.84 ± 8.23  -3.1 (-7.1, 0.9)  36.05 ± 8.38 37.97 ± 10.18 3.8 (-0.5, 8.2) 37.04 ± 11.27 38.31 ± 9.60 0.2 (-4.9, 5.4) 0.171 
PUFA (g/d) 11.18 ± 2.93 10.65 ± 4.21  -0.8 (-2.4, 0.7) 10.87 ± 3.81 11.94 ± 4.42 0.7 (0.7, 2.0) 10.53 ± 4.83 10.71 ± 3.29 0.2 (-1.1, 1.5) 0.464 
Cholesterol (mg/d) 365 ± 108 355 ± 125  -14 (-65, 36) 336 ± 136 342 ± 103 33 (-21, 86) 345 ± 124 360 ± 162 25 (-55, 61) 0.462 
Vitamin C (mg/d) 118 ± 75 125 ± 83 11 (-11, 32) 124 ± 59 121 ± 68  -2.6 (-21, 16) 129 ± 87 133 ± 91  -12 (-37,11) 0.507 
Vitamin A (µgRE||/d) 605 ± 255 688 ± 340 89 (-195, 374) 696 ± 532 729 ± 343 83 (-125, 231) 725 ± 452 709 ± 481  -65 (-158,77) 0.234 
Vitamin E (mg/d) 9.28 ± 2.82 9.65 ± 3.22  -0.5 (-1.5, 0.5) 9.55 ± 2.86 9.47 ± 3.34  -0.1 (-1, 0.8) 9.37 ± 2.98 10.29 ± 4.65 0.5 (-0.4, 1.3) 0.399 
Folic acid (µg/d) 493 ± 166 454 ± 155  -43 (-121,35) 394 ± 138 443 ± 143 64 (-20, 148) 484 ± 186 498 ± 226 11 (-45, 67) 0.335 
Calcium (mg/d) 714 ± 73 718 ± 36 61 (-24, 146) 663 ± 21 678 ± 35 39 (-47, 125) 731 ± 31 712 ± 30  -70 (-200, 605) 0.342 
Magnesium (mg/d) 398 ± 74 345 ± 92  -87 (-420, 245) 316 ± 94 339 ± 95 97 (-100, 295) 368 ± 96 342 ± 106  -31 (-40.1, 34.0) 0.551 
Manganese (mg/d) 2.77 ± 1.17 2.66 ± 1.09  -0.1 (-0.7, 0.5) 2.61 ± 1.06 2.72 ± 1.26 0.1 (-0.3, 0.8) 2.76 ± 1.41 2.82 ± 1.18 0.2 (-1.0, 5.4) 0.617 
Potassium (mg/d) 2918 ± 718 3119 ± 673 87 (-149, 323) 2967 ± 751 3089 ± 850 49 (-186, 285) 3254 ± 790 3121 ± 955  -66 (-271, 139) 0.515 
Selenium (µg/d) 146 ± 37 139 ± 37  -21 (-186, 144) 134 ± 35 136 ± 38 47 (-121, 215) 131 ± 33 136 ± 33 52 (-85, 189) 0.790 
Sodium (mg/d) 2296 ± 161 2298 ± 198  -127 (-434, 180) 2137 ± 202 2205 ± 191 359 (-750, 794) 2293 ± 213 2278 ± 121  -87 (-294, 119) 0.218 
Zinc (mg/d) 10.18 ± 1.59 10.48 ± 2.42 1.1 (-4.6, 5.8) 10.32 ± 2.64 9.56 ± 2.40  -2.2 (-5.7, 2.2) 10.07 ± 2.54 10.40 ± 2.21  -2.5 (-5.4, 3.4) 0.549 
Total polyphenols (mg/d) 308 ± 134 318 ± 142 31 (-23, 87) 320 ± 168 311 ± 146  -33 (-89,23) 313 ± 169 327 ± 170  -32 (-77, 13) 0.146 
*
 Excluding the energy, nutrient and total polyphenol contributions from the tested beverages. Results are expressed as †mean ± SD (n=67) and 
‡mean differences (95% CI) between after and before each intervention. Before each intervention is the value of the previous intervention or the 
baseline in the first intervention. §P value of the repeated-measures ANOVA from the differences between interventions. No changes were 
observed between after and before the intervention, measured by a Student’s t test for paired samples. ||Retinol Equivalents.
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